Leiters Health Rocuronium Bromide Recall: Sterility Failure Poses High Supply Chain Risk
Denver Solutions, LLC DBA Leiters Health has initiated a Class II recall for 16,655 syringes of Rocuronium Bromide due to sterility assurance issues, specifically leaking/damaged syringes. This nationwide recall, impacting Lot #:2530023, Exp.: 7/12/2025, necessitates immediate action from procurement and regulatory teams to mitigate supply chain disruptions and ensure patient safety with this critical neuromuscular blocker.
FDA Class II Recall: Leiters Health Rocuronium Bromide Sterility Failure
Denver Solutions, LLC DBA Leiters Health has initiated a Class II recall for its Rocuronium Bromide 50 mg per 5mL (10mg per mL), 5mL Single Dose Syringes. This critical action, designated Recall Number D-0374-2025, commenced on March 31, 2025, and is classified as ongoing by the FDA as of April 30, 2025. The primary reason for this recall is a severe lack of assurance of sterility, evidenced by leaking and damaged syringes. For procurement directors and supply chain VPs, this means immediate action is required to identify and quarantine 16,655 affected syringes from Lot #:2530023, which carries an expiration date of July 12, 2025. The NDC for the recalled product is 71449-004-11. This sterility breach for an injectable drug like Rocuronium Bromide, a neuromuscular blocker essential in surgical procedures and mechanical ventilation, represents a high-risk event. The nationwide distribution pattern across the United States implies a broad impact on hospital pharmacies, surgical centers, and emergency services. Regulatory affairs heads must ensure their organizations are fully compliant with the recall instructions, including proper documentation and communication with affected downstream users. Failure to promptly remove compromised product from the supply chain exposes patients to potential infections and carries significant legal, financial, and reputational risks for all entities involved in its distribution and use.
Leiters Health Operational Footprint and Product Scope
Denver Solutions, LLC DBA Leiters Health operates from its facility located at 13796 Compark Blvd, Englewood, CO 80112-7145, within the United States. This facility is the origin point for the recalled Rocuronium Bromide 50 mg per 5mL (10mg per mL) single-dose syringes. While specific details regarding the facility's overall production capacity, key markets beyond the U.S., or its full product portfolio are not publicly available within the provided intelligence, the current recall highlights a critical quality control vulnerability at this site. For business development executives and procurement teams, the lack of granular public data on Leiters Health's operational scale and market share for Rocuronium Bromide underscores a broader challenge in supplier due diligence. Without specific FEI numbers or detailed capacity figures, assessing the full systemic impact of this recall and the company's ability to recover and maintain supply becomes more complex. This incident serves as a reminder for organizations to conduct thorough, independent audits of their critical suppliers, extending beyond publicly available information, to understand manufacturing processes, quality systems, and potential single points of failure at facilities like the Englewood, CO site.
Critical Supply Chain Impact: Rocuronium Bromide Market Disruption
The nationwide recall of 16,655 syringes of Rocuronium Bromide by Denver Solutions, LLC DBA Leiters Health presents a tangible supply chain disruption for a critical care pharmaceutical. Rocuronium Bromide is an essential non-depolarizing neuromuscular blocker used to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation. Any interruption in its supply can directly impact surgical schedules, intensive care unit operations, and emergency medical services across the United States. Procurement directors must immediately assess their current inventory of Rocuronium Bromide, specifically checking for the affected Lot #:2530023 from Leiters Health. The immediate business imperative is to prevent stockouts while simultaneously ensuring patient safety by removing compromised product. Supply chain VPs should activate contingency plans, including exploring existing contracts with other suppliers and initiating rapid qualification processes for new sources, if necessary. The Class II classification indicates that use of the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote, but the sterility concern for an injectable drug elevates the risk profile significantly for healthcare providers and their patients.
Strategic Sourcing: Navigating Rocuronium Bromide Supplier Diversification
In the wake of Leiters Health's Rocuronium Bromide recall, procurement teams are faced with the immediate challenge of ensuring continuity of supply for this critical anesthetic agent. While specific alternative suppliers are not identified in the available intelligence, the incident underscores the strategic imperative for pharmaceutical companies and healthcare systems to maintain a diversified supplier base for essential medicines. Relying on a single source or a limited number of suppliers for high-volume, critical injectables like Rocuronium Bromide inherently increases supply chain vulnerability to quality issues or manufacturing disruptions. Business development executives should recognize this as an opportunity to assess and strengthen their supplier relationships, prioritizing those with robust quality management systems and a proven track record of compliance. For procurement directors, this means proactively identifying and qualifying secondary or tertiary sources for Rocuronium Bromide, even if current supply appears stable. The qualification timeline for new pharmaceutical suppliers, particularly for sterile injectables, can be extensive, often spanning several months to a year due to stringent regulatory requirements and internal validation processes. Initiating these discussions now, rather than waiting for a crisis, is crucial for building long-term supply chain resilience and mitigating future commercial risks associated with similar recall events.
Broader Regulatory Context: Escalating Sterility Risks in Injectable Pharmaceuticals
The recall of Rocuronium Bromide by Denver Solutions, LLC DBA Leiters Health due to sterility assurance issues is not an isolated incident but rather indicative of a persistent regulatory challenge within the injectable pharmaceutical sector. The FDA continues to prioritize oversight of sterile manufacturing, and similar events frequently emerge. For instance, a parallel Class II recall occurred recently when Essential Wellness Pharma's Progesterone Injection also failed sterility assurance, as reported in June 2026. This trend highlights the FDA's heightened scrutiny on aseptic processing and the integrity of sterile drug products. Regulatory affairs heads must interpret these recurring sterility-related recalls as a clear signal of the FDA's unwavering focus on Current Good Manufacturing Practices (CGMP) for sterile products. This means that manufacturing facilities, particularly those producing injectables, are under constant pressure to demonstrate robust environmental controls, stringent personnel training, and impeccable process validation. Companies failing to meet these standards face not only recalls but also potential Warning Letters, import alerts, and significant operational disruptions. The commercial implication is clear: investment in state-of-the-art quality systems and continuous compliance monitoring is not merely a regulatory burden but a fundamental requirement for market access and sustained business operations in the global chemical and life sciences industry.
Leiters Health Remediation and Future Compliance Outlook
The ongoing Class II recall initiated by Denver Solutions, LLC DBA Leiters Health for its Rocuronium Bromide syringes mandates a comprehensive remediation effort by the company. As the recall status is 'Ongoing,' the firm is expected to be actively engaged in identifying the root cause of the leaking/damaged syringes and the associated lack of sterility assurance. This typically involves a thorough investigation into manufacturing processes, packaging integrity, quality control procedures, and environmental monitoring at their Englewood, CO facility. Regulatory affairs heads should anticipate that the FDA will closely monitor Leiters Health's corrective and preventive actions (CAPA) to ensure they are robust and effectively address the identified deficiencies. For business development executives, the long-term impact hinges on Leiters Health's ability to demonstrate swift and effective remediation. A failure to adequately address the sterility issues could lead to further regulatory actions, including potential FDA Warning Letters, increased inspections, or even product withdrawal from the market. Procurement directors and supply chain VPs should monitor the progress of this recall and Leiters Health's subsequent compliance status closely. While the immediate focus is on managing the current supply disruption, the broader commercial implication is the need for confidence in a supplier's enduring commitment to quality and regulatory adherence, especially for critical care products like Rocuronium Bromide.